MDXG vs RCEL
MDXG: MiMedx develops and distributes advanced wound care biologics including human placental allografts and expanding xenograft/collagen products to treat chronic and hard-to-heal wounds across surgical and clinical settings. RCEL: A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform.
Side-by-side fundamentals
| Metric | MDXG | RCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.17 | $4.94 | |
| Market cap as of 2026-07-23 | $621M | $157M | |
| P/E as of 2026-07-23 | 20.23 | n/a | |
| Net margin as of 2026-07-23 | +7.9% | -62.7% | MDXG higher |
| Gross margin as of 2026-07-23 | +81.0% | +82.1% | RCEL higher |
| Operating margin as of 2026-07-23 | +10.2% | -54.6% | MDXG higher |
| ROE as of 2026-07-23 | +12.9% | -337.9% | MDXG higher |
| ROA as of 2026-07-23 | +9.7% | -78.9% | MDXG higher |
| Debt / equity as of 2026-07-23 | 0.07 | 9.39 | MDXG lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.5% | +1.0% | MDXG higher |
| Revenue CAGR (3y) SEC XBRL | +16.1% | +27.7% | RCEL higher |
| Beta as of 2026-07-23 | 1.47 | 1.84 | |
| 1-year return as of 2026-07-22 close | -35.0% | -15.0% | RCEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.